GlassScriptPhysician profile
Gerardo Soto
NPI 1902197445
$1,854.66
in general payments reported to CMS, 2019-2025
23 companies · $49.38 in 2025
The $49.38 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $255 · 2021: $610 · 2022: $261 · 2023: $141 · 2024: $89.15 · 2025: $49.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $247.89 | 2020-2021 | |
| Abbvie INC. | $222.19 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $220.73 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $189.32 | 2019-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $149.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $112.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $82.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $67.27 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $55.73 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $55.58 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $54.78 | 2023-2024 | Rybelsus, Ozempic |
| Sunovion Pharmaceuticals INC. | $54.60 | 2021 | |
| Amarin Pharma, INC. | $47.26 | 2019-2022 | |
| Abbott Laboratories | $38.19 | 2022-2024 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.18 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $29.48 | 2021 | |
| Protega Pharmaceutials INC | $28.83 | 2025 | Roxybond |
| Daiichi Sankyo INC. | $21.06 | 2019 | |
| Exact Sciences Corporation | $18.54 | 2023 | Cologuard Collection Kit |
| Alkermes, INC. | $15.49 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.56 | 2021 | |
| Galderma Laboratories, L.P. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.